ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
ANI Pharmaceuticals launched Duloxetine Delayed-Release Capsules in 20, 30 and 60 mg strengths, the generic version of the reference listed drug Cymbalta. U.S. annual sales for the product totaled approximately $247 million based on August 2026 moving annual total IQVIA data, and the company describes it as a limited-competition market where it can support stable supply.
Key figures
- Drug Name
- Duloxetine Delayed-Release Capsules (generic of Cymbalta)
- Market sales basis
- August 2026 MAT IQVIA data
- Strengths launched
- ["20 mg","30 mg","60 mg"]
- Us annual market sales
- $247 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.